

8a
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unjess it contains a valid QMB control number

		Under the Paperwork Reduction	Act of 1995	, no persons :	are required to respon	omplete if I	Known		noer
Substitute #	nr fnom 4	449A/PTO		Applica	tion Number	ompiete if I	Wolf 1 D D	7017	
Substitute for form 1449A/PTO INFORMATION DISCLOSURE				Filing Date First Named Inventor					
						e Henry			
STA	TEM	ENT BY APPLICAN	T	Art Unit		105	5		
	01			Examin	er Name	Ami			
Sheet		as many sheets as necessary) of 2		Attome	y Docket Numbe		PCT/US		
			11.6	DATENT	OCUMENTS				
Examiner	Cite	Document Number		ation Date	Name of Pate	otee or	Pages, Columns, Lines	. Where Relevant	
Initials*	Cite No.			D-YYYY	Applicant of Cited		Passages or Relevant	.,	
ALC	 	US-20040042996	03-04	-2004	Pauly et al.	·····	Figures Appear	 	
	 	US-20040042990	03-04-2004		Pauly et al.				
ALC	-	US-	100		1 45., 51.				
	<u> </u>					· · · · · · · · · · · · · · · · · · ·			
	ļ	US-	ļ						
		US-							
	ļ	US-	 						
	ļ	US-	↓						
	ļ	US-	ļ						
	ļ	US-							
	ļ	US-	 		ļ				
		US-	ــــــ		<u> </u>				
	<u> </u>	US-	<u> </u>		ļ				
	<u> </u>	US-	<u> </u>		ļ				
		US-	ļ						
		US-	4						
	<u> </u>	US-			<u> </u>				
					N PATENT DOC			T- 01	1
Examiner Initials*	Cite No.	Foreign Patent Document Country Code Number Kind Code ((f known)	Publication Date MM-DD-YYY	Name of Pat Applicant of Co			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
37.0		EP 1 213 024 (abstract)		06-12-20	02 Serobiolog	iques Lab S	Α		
ALC		(equiv. to US 2004004	2996)			•		-	
	1	WO 02/45728 (abstract)		06-13-20	02 Cognis Fra	nce SA			
$\vdash \!\! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! $	+-	(equiv. to US 2004004 EP 0 747 048	1032)	12-11-19	96 Yakurioaki	Chuo Kenk	cyusho		1
ALC	2, 0, 1, 0, 1		02-01-19		Mitsubishi Kasel Corpo.				
Auc	+	0, 0 020211 (220220)	<u>'</u>			<u></u>			1
	+								
	+								
 	+								
	+								\prod
									
<u> </u>	+-	 							
<u> </u>	+	 							
	+	 							
<u></u>	4=					Date	T		
	Examiner /Amy Clark/			k/		Considered	02/	20/2007	

JC05 Reg'd PCT/PTO, 16 JUN 2005

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			Complete if Known A 40 2 7 0				
Substitu	Substitute for form 1449A/PTO		Application Number	340 337 417			
INFORMATION DICCLOSURE		Filing Date					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Florence Henry			
			Art Unit	iuss			
			Examiner Name	AMUCIAIK			
Sheet	2	of 2	Attorney Docket Number	C 2766 PCT/US			

kaminer	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ilem (book, magazine, journal, serial,	Т	1
ilials*	No.1	symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
ALC		Charrouf et al., "Ethnoeconomical, Ethnomedical, and Phytochemical Study of Argania Spinosa (L.) Skeels: A Review", Jour. of Ethnopharmacology, vol. 67, 1992, pgs 7-14, XP002242296		
		Z. Charrouf, "Triterpenes et Sterols Extraits de la Pulpe D'Argania Spinosa (L.) Sapotaceae", Plantes Medicinales et Phytotherapie, vol.25, 1991, pgs 112-117; XP000619575		HISTIV
		R. Maurin, "L'Huile D'Argan Argania Spinosa (L.) Skeels Sapotaceae, Mise au Point", O.C.L. Oleagineux Corps Gras Lipides, vol. 39, 1992, pgs 139-146; XP002037529		PRISTIC
		Alaqui et al., "Activite Analgesique et Anti-Inflammatoire des Saponines D'Argania Spinosa Analgesic and Antiinflammatory Activity of Argania Spinosa Saponins", Annales Pharmaceutiques Françaises, vol.56, 1998, pgs 220-228; XP000995497		
		Charrouf et al., "Triterpenoid Saponins from Argania Spinosa", Phytochemistry, vol.31, 1992, pgs 2079-2086; XP001157414		
		Tahrouch et al., "Polyphenol Investigation of Argania Spinosa (Sapotaceae) Endemic Tree from Morocco", Acta Botanica Gallica, vol.147, 2000, pgs 225-232; XP000996078		PROSTRY
<u> </u>		Hiipakka et al., "Structure-activity Relationships for Inhibition of Human 5-alpha-reductases by polyphenols", Biochemical Pharmacology, vol.63, 2002, pgs 1165-1176; XP002242332		
∇		Alaoui et al., "Activite analgesique et anti-inflammatoire des saponines d'Argania spinosa", Annales pharmaceutique francaises, 1998, pgs 220-228		CHOSTOC
ALC		Oulad-Ali et al., "Structure Elucidation of Three Triterpene Glycosides from the Trunk of Argania spinosa", J.Nat.Prod., 1996, pgs 193-195		1.000
	-	Hagers Handbuch-der-pharmazeutischen Praxis, vol. 2, 1991, pgs-1926-1939		DON T
ALC		Bernard et al., "Expression of type 1 5-alpha-reductase and metabolism of testosterone in reconsructed human epidermis (SkinEthic®): a new model for screening skin-targeted androgen modulators", Int.J.Cosmetic Science, pgs 397-407		\ \int
ALC		Berrada et al., "Mise en évidence expérimentale des effets antihypertenseurs et hypocholestérolémiants de l'huile d'Argan, Argania sideroxylon", Thérapie 2000, pgs 375-378 (listed on European Search Report which is unavailable).	_	Amstru

Examiner Signature	/Amy Clark/	Date Considered	02/20/2007	
			the state of the s	

Examiner: tritlal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Palent Documents at www.uspto.exy or MPEP 901,04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if Emperor must precede the serial number of the patent of the USPTO to process). This collection of information is required by 37 CFR 1.97 and 1.98. The Information is statished.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting an application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or the completed application form to the USPTO. Time will vary depending upon the individ

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DSO/mc G/IDC/C2766idc